Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker JSPR
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | SCHEDULE 13G | JSPR Jasper Therapeutics, Inc. | Michael Cho | 1.85M | 5.6% | SCHEDULE 13G ↗ |
| Nov 13, 2026 | SCHEDULE 13G | JSPR Jasper Therapeutics, Inc. | Affinity Asset Advisors, LLC | 1.85M | 5.6% | SCHEDULE 13G ↗ |
| Oct 28, 2026 | SCHEDULE 13G | JSPR Jasper Therapeutics, Inc. | Bank of America Corp /DE/ | 2.13M | 6.4% | SCHEDULE 13G ↗ |
| Aug 17, 2026 | SCHEDULE 13G | JSPR Jasper Therapeutics, Inc. | Kapoor Vishal | 35,013 | 0.1% | SCHEDULE 13G ↗ |
| Aug 17, 2026 | SCHEDULE 13G | JSPR Jasper Therapeutics, Inc. | Venkataraman Balaji | 3.36M | 9.9% | SCHEDULE 13G ↗ |
| Aug 17, 2026 | SCHEDULE 13G | JSPR Jasper Therapeutics, Inc. | Morgan Adam | 3.36M | 9.9% | SCHEDULE 13G ↗ |
| Aug 17, 2026 | SCHEDULE 13G | JSPR Jasper Therapeutics, Inc. | Velan Capital Management LLC | 3.36M | 9.9% | SCHEDULE 13G ↗ |
| Aug 17, 2026 | SCHEDULE 13G | JSPR Jasper Therapeutics, Inc. | Velan Capital Investment Management LP | 3.36M | 9.9% | SCHEDULE 13G ↗ |
| Aug 17, 2026 | SCHEDULE 13G | JSPR Jasper Therapeutics, Inc. | Avego Management LLC | 243,563 | 0.7% | SCHEDULE 13G ↗ |
| Aug 17, 2026 | SCHEDULE 13G | JSPR Jasper Therapeutics, Inc. | Avego Healthcare Capital Holdings, LLC | 243,563 | 0.7% | SCHEDULE 13G ↗ |
| Aug 17, 2026 | SCHEDULE 13G | JSPR Jasper Therapeutics, Inc. | Avego Healthcare Capital, L.P. | 243,563 | 0.7% | SCHEDULE 13G ↗ |
| Aug 17, 2026 | SCHEDULE 13G | JSPR Jasper Therapeutics, Inc. | Velan Horizon GP LLC | 82,008 | 0.2% | SCHEDULE 13G ↗ |
| Aug 17, 2026 | SCHEDULE 13G | JSPR Jasper Therapeutics, Inc. | Velan Horizon Fund LP | 82,008 | 0.2% | SCHEDULE 13G ↗ |
| Aug 17, 2026 | SCHEDULE 13G | JSPR Jasper Therapeutics, Inc. | Velan Capital Holdings LLC | 3.04M | 8.9% | SCHEDULE 13G ↗ |
| Aug 17, 2026 | SCHEDULE 13G | JSPR Jasper Therapeutics, Inc. | Velan Capital Master Fund LP | 3.04M | 8.9% | SCHEDULE 13G ↗ |
| Jul 20, 2026 | SCHEDULE 13D/A (amended) | JSPR Jasper Therapeutics, Inc. | Kapoor Vishal | 35,013 | 0.1% | SCHEDULE 13D/A ↗ |
| Jul 20, 2026 | SCHEDULE 13D/A (amended) | JSPR Jasper Therapeutics, Inc. | Venkataraman Balaji | 3.35M | 9.9% | SCHEDULE 13D/A ↗ |
| Jul 20, 2026 | SCHEDULE 13D/A (amended) | JSPR Jasper Therapeutics, Inc. | Morgan Adam | 3.35M | 9.9% | SCHEDULE 13D/A ↗ |
| Jul 20, 2026 | SCHEDULE 13D/A (amended) | JSPR Jasper Therapeutics, Inc. | Velan Capital Management LLC | 3.35M | 9.9% | SCHEDULE 13D/A ↗ |
| Jul 20, 2026 | SCHEDULE 13D/A (amended) | JSPR Jasper Therapeutics, Inc. | Velan Capital Investment Management LP | 3.35M | 9.9% | SCHEDULE 13D/A ↗ |
| Jul 20, 2026 | SCHEDULE 13D/A (amended) | JSPR Jasper Therapeutics, Inc. | Avego Management LLC | 245,328 | 0.7% | SCHEDULE 13D/A ↗ |
| Jul 20, 2026 | SCHEDULE 13D/A (amended) | JSPR Jasper Therapeutics, Inc. | Avego Healthcare Capital Holdings, LLC | 245,328 | 0.7% | SCHEDULE 13D/A ↗ |
| Jul 20, 2026 | SCHEDULE 13D/A (amended) | JSPR Jasper Therapeutics, Inc. | Avego Healthcare Capital, L.P. | 245,328 | 0.7% | SCHEDULE 13D/A ↗ |
| Jul 20, 2026 | SCHEDULE 13D/A (amended) | JSPR Jasper Therapeutics, Inc. | Velan Horizon GP LLC | 82,304 | 0.2% | SCHEDULE 13D/A ↗ |
| Jul 20, 2026 | SCHEDULE 13D/A (amended) | JSPR Jasper Therapeutics, Inc. | Velan Horizon Fund LP | 82,304 | 0.2% | SCHEDULE 13D/A ↗ |
| Jul 20, 2026 | SCHEDULE 13D/A (amended) | JSPR Jasper Therapeutics, Inc. | Velan Capital Holdings LLC | 3.02M | 8.9% | SCHEDULE 13D/A ↗ |
| Jul 20, 2026 | SCHEDULE 13D/A (amended) | JSPR Jasper Therapeutics, Inc. | Velan Capital Master Fund LP | 3.02M | 8.9% | SCHEDULE 13D/A ↗ |
| Jul 10, 2026 | SCHEDULE 13G/A (amended) | JSPR Jasper Therapeutics, Inc. | Israel A. Englander | 486,933 | 1.7% | SCHEDULE 13G/A ↗ |
| Jul 10, 2026 | SCHEDULE 13G/A (amended) | JSPR Jasper Therapeutics, Inc. | Millennium Group Management LLC | 486,933 | 1.7% | SCHEDULE 13G/A ↗ |
| Jul 10, 2026 | SCHEDULE 13G/A (amended) | JSPR Jasper Therapeutics, Inc. | Millennium Management LLC | 486,933 | 1.7% | SCHEDULE 13G/A ↗ |
| Jul 10, 2026 | SCHEDULE 13G/A (amended) | JSPR Jasper Therapeutics, Inc. | Integrated Core Strategies (US) LLC | 486,454 | 1.7% | SCHEDULE 13G/A ↗ |
| May 12, 2026 | SCHEDULE 13G/A (amended) | JSPR Jasper Therapeutics, Inc. | Morgan Stanley Capital Services LLC | 1.29M | 4.6% | SCHEDULE 13G/A ↗ |
| May 12, 2026 | SCHEDULE 13G/A (amended) | JSPR Jasper Therapeutics, Inc. | Morgan Stanley | 1.33M | 4.8% | SCHEDULE 13G/A ↗ |
| May 8, 2026 | SCHEDULE 13G/A (amended) | JSPR Jasper Therapeutics, Inc. | Guy Levy | 276,312 | 1.0% | SCHEDULE 13G/A ↗ |
| May 8, 2026 | SCHEDULE 13G/A (amended) | JSPR Jasper Therapeutics, Inc. | Soleus GP, LLC | 276,312 | 1.0% | SCHEDULE 13G/A ↗ |
| May 8, 2026 | SCHEDULE 13G/A (amended) | JSPR Jasper Therapeutics, Inc. | Soleus Capital Management, L.P. | 276,312 | 1.0% | SCHEDULE 13G/A ↗ |
| May 8, 2026 | SCHEDULE 13G/A (amended) | JSPR Jasper Therapeutics, Inc. | Soleus Capital Group, LLC | 118,912 | 0.4% | SCHEDULE 13G/A ↗ |
| May 8, 2026 | SCHEDULE 13G/A (amended) | JSPR Jasper Therapeutics, Inc. | Soleus Capital, LLC | 118,912 | 0.4% | SCHEDULE 13G/A ↗ |
| May 8, 2026 | SCHEDULE 13G/A (amended) | JSPR Jasper Therapeutics, Inc. | Soleus PE GP III, LLC | 157,400 | 0.6% | SCHEDULE 13G/A ↗ |
| May 8, 2026 | SCHEDULE 13G/A (amended) | JSPR Jasper Therapeutics, Inc. | Soleus Private Equity GP III, LLC | 157,400 | 0.6% | SCHEDULE 13G/A ↗ |
| May 8, 2026 | SCHEDULE 13G/A (amended) | JSPR Jasper Therapeutics, Inc. | Soleus Private Equity Fund III, L.P. | 157,400 | 0.6% | SCHEDULE 13G/A ↗ |
| May 8, 2026 | SCHEDULE 13G/A (amended) | JSPR Jasper Therapeutics, Inc. | Soleus Capital Master Fund, L.P. | 118,912 | 0.4% | SCHEDULE 13G/A ↗ |
| May 8, 2026 | SCHEDULE 13G/A (amended) | JSPR Jasper Therapeutics, Inc. | Goldman Sachs & Co. LLC | 128,862 | 0.5% | SCHEDULE 13G/A ↗ |
| May 8, 2026 | SCHEDULE 13G/A (amended) | JSPR Jasper Therapeutics, Inc. | The Goldman Sachs Group, Inc. | 128,862 | 0.5% | SCHEDULE 13G/A ↗ |
| Feb 25, 2026 | SCHEDULE 13G | JSPR Jasper Therapeutics, Inc. | Israel A. Englander | 1.63M | 5.8% | SCHEDULE 13G ↗ |
| Feb 25, 2026 | SCHEDULE 13G | JSPR Jasper Therapeutics, Inc. | Millennium Group Management LLC | 1.63M | 5.8% | SCHEDULE 13G ↗ |
| Feb 25, 2026 | SCHEDULE 13G | JSPR Jasper Therapeutics, Inc. | Millennium Management LLC | 1.63M | 5.8% | SCHEDULE 13G ↗ |
| Feb 25, 2026 | SCHEDULE 13G | JSPR Jasper Therapeutics, Inc. | Integrated Core Strategies (US) LLC | 1.62M | 5.8% | SCHEDULE 13G ↗ |
| Feb 18, 2026 | SCHEDULE 13D/A (amended) | JSPR Jasper Therapeutics, Inc. | Abingworth Bioventures VII LP | 1.09M | 3.8% | SCHEDULE 13D/A ↗ |
| Feb 18, 2026 | SCHEDULE 13D/A (amended) | JSPR Jasper Therapeutics, Inc. | Abingworth LLP | 1.09M | 3.8% | SCHEDULE 13D/A ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 7:24 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances